guest ::
| Home > Publications database > Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI. |
| Home > Publications database > Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI. |
| Journal Article | DKFZ-2026-01436 |
; ; ; ; ; ; ; ; ; ; ;
2026
SpringerOpen
Heidelberg
Abstract: The aim of this study was to investigate the limits of diagnostics and therapy planning for patients with prostate cancer using non-time-of-flight 18F/68Ga-PSMA PET/MRI under clinically challenging imaging conditions with small lesion sizes and low uptake. Lesion detectability and quantification accuracy were evaluated for different acquisition and reconstruction parameters in a systematic phantom study and subsequent on patient data.PET/MRI measurements were performed using a small lesion NEMA phantom. PET data were acquired for nine different activity concentrations (AC). Data of a longer single-bed protocol in the pelvis or a shorter whole-body protocol were reconstructed using relative or absolute scatter correction (SC). PET images were analysed considering a ± 25% deviation range between imaged and true AC as acceptable. Thirteen PSMA-PET/MRI patients with primary lesions or lymph node metastasis < 12 mm in the pelvis were included in this study. The presence of the halo artefact was evaluated in six 18F-PSMA and seven 68Ga-PSMA PET/MRI patients. For 21 lesions (diameter 6.4-12.3 mm) in total, the AC was quantified.For both radiotracers, the 9.7 mm sphere was still visible at 0.16 kBq/mL with emission times > 40 min. The 3.7 mm sphere was only detectable at 22 kBq/mL with emission times > 4 min. All spheres ≥ 6.5 mm provide acceptable quantification at an AC of 1.32 kBq/mL for 18F PET/MRI protocols of ≥ 12 min and 2.75 kBq/mL for 68Ga PET/MRI protocols. In phantom data, no halo artefact was observable and different SC methods had no impact on quantification. 4/6 18F-PSMA patients and 7/7 68Ga-PSMA patients showed a halo around the bladder using relative SC, which could be reduced in all patients using absolute SC. Comparing the minimum quantifiable AC (MQAC) from in the phantom study as a threshold to the patient data, all lesions provided acceptable quantification with values > MQAC (AC 3.3-108.5 kBq/mL) for equal reconstruction and acquisition parameters.The results demonstrated that the detection of lesions in the sub-centimetre range and a reliable quantification of 18F/68Ga-PSMA uptake using standard acquisition and reconstruction parameters within clinical PET/MRI protocols is possible. This allows for an individual assessment of potential therapy options for each patient.
Keyword(s): 177Lu-PSMA therapy ; 18F-PSMA PET/MR ; 68Ga-PSMA PET/MR ; Prostate cancer ; Radionuclide therapy planning
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
